Novel therapies for metastatic prostate cancer

References

• Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023 Jan;73(1):17–48. doi: 10.3322/caac.21763
   PubMed Web of Science ®Google Scholar
• Sayegh N, Swami U, Agarwal N. Recent advances in the management of metastatic prostate cancer. JCO Oncol Pract. 2022 Jan;18(1):45–55. doi: 10.1200/OP.21.00206
   PubMedGoogle Scholar
• Shore ND, Laliberté F, Ionescu-Ittu R, et al. Real-world treatment patterns and overall survival of patients with metastatic castration-resistant prostate cancer in the US prior to PARP inhibitors. Adv Ther. 2021 Aug;38(8):4520–4540. doi: 10.1007/s12325-021-01823-6
   PubMed Web of Science ®Google Scholar
• Cancer Stat Facts: Prostate Cancer: National Cancer Institute; 2023 [cited 2023 Aug 26]. Available from: https://seer.cancer.gov/statfacts/html/prost.html
   Google Scholar
• Martinez I, Kernan K, Piasecki P, et al. A novel abiraterone acetate oral suspension for patients with metastatic prostate cancer: an open-label, phase 3, randomized trial. J Clin Oncol. 2023;41(16_suppl):5052.
   Google Scholar
• Ye D-W, Gu C, Hua L, et al. Deutenzalutamide, an oral deuterated androgen receptor inhibitor, vs placebo for patients with mCRPC who have experienced treatment failure with abiraterone and docetaxel: results of the HC-1119-04 phase 3 trial. J Clin Oncol. 2023;41(16_suppl):5065.
   Web of Science ®Google Scholar
• Fujita K, Nonomura N. Role of Androgen Receptor in Prostate Cancer: A Review. World J Mens Health. 2019 Sep;37(3):288–295. doi: 10.5534/wjmh.180040
   PubMedGoogle Scholar
• Maurice-Dror C, Le Moigne R, Vaishampayan U, et al. A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer. Invest New Drugs. 2022 Apr;40(2):322–329. doi: 10.1007/s10637-021-01202-6
   PubMed Web of Science ®Google Scholar
• Pachynski RK, Iannotti N, Laccetti AL, et al. Oral EPI-7386 in patients with metastatic castration-resistant prostate cancer. JCO. 2023/Feb/20;41(6_suppl):177. doi: 10.1200/JCO.2023.41.6_suppl.177
   Google Scholar
• Laccetti AL, Chatta GS, Iannotti N, et al. Phase 1/2 study of EPI-7386 in combination with enzalutamide (enz) compared with enz alone in subjects with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2023;41(6_suppl):179. doi: 10.1200/JCO.2023.41.6_suppl.179
   Google Scholar
• Moll JM, Hofland J, Teubel WJ, et al. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling. Prostate. 2022 Apr;82(5):505–516. doi: 10.1002/pros.24297
   PubMed Web of Science ®Google Scholar
• Fizazi K, Cook N, Barthélémy P, et al. Phase 1 results of the ODM-208 first-in-human phase 1-2 trial in patients with metastatic castration-resistant prostate cancer (CYPIDES). J Clin Oncol. 2022;40(6_suppl):18.
   Google Scholar
• Arora VK, Schenkein E, Murali R, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 2013 Dec 5;155(6):1309–1322. doi: 10.1016/j.cell.2013.11.012
   PubMed Web of Science ®Google Scholar
• Morris MJ, Linch MD, Crabb SJ, et al. Phase 1 efficacy and pharmacodynamic results of exicorilant + enzalutamide in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2023;41(6_suppl):145.
   PubMedGoogle Scholar
• Desai K, Serritella AV, Stadler WM, et al. Phase I trial of enzalutamide (Enz) plus the glucocorticoid receptor antagonist relacorilant (rela) for patients with metastatic castration resistant prostate cancer. J Clin Oncol. 2023;41(16_suppl):5062.
   Web of Science ®Google Scholar
• Burslem GM, Smith BE, Lai AC, et al. The advantages of targeted protein degradation over inhibition: an RTK Case study. Cell Chem Biol. 2018 Jan 18;25(1):67–77.e3. doi: 10.1016/j.chembiol.2017.09.009
   PubMed Web of Science ®Google Scholar
• Jia X, Han X. Targeting androgen receptor degradation with PROTACs from bench to bedside. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2023 Feb;158:114112. doi: 10.1016/j.biopha.2022.114112
   PubMed Web of Science ®Google Scholar
• Gao X, Burris III HA, Vuky J, et al. Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC). JCO. 2022;40(6_suppl):17. doi: 10.1200/JCO.2022.40.6_suppl.017
   Google Scholar
• Arvinas announces interim data from the ARV-766 phase 1/2 dose escalation and expansion trial showing promising signals of efficacy in late-line mCRPC, Including In Patients With AR L702H Mutations Arvinas2023 [cited 2023 Aug 15]. Available from: https://ir.arvinas.com/news-releases/news-release-details/arvinas-announces-interim-data-arv-766-phase-12-dose-escalation
   Google Scholar
• Papa A, Pandolfi PP. The PTEN–PI3K axis in cancer. Biomolecules. 2019 Apr 17;9(4):153. doi: 10.3390/biom9040153
   PubMed Web of Science ®Google Scholar
• Jamaspishvili T, Berman DM, Ross AE, et al. Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol. 2018 Apr;15(4):222–234. doi: 10.1038/nrurol.2018.9
   PubMed Web of Science ®Google Scholar
• Vidotto T, Melo CM, Castelli E, et al. Emerging role of PTEN loss in evasion of the immune response to tumours. Br J Cancer. 2020 Jun;122(12):1732–1743. doi: 10.1038/s41416-020-0834-6
   PubMed Web of Science ®Google Scholar
• Carver BS, Chapinski C, Wongvipat J, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011 May 17;19(5):575–586. doi: 10.1016/j.ccr.2011.04.008
   PubMed Web of Science ®Google Scholar
• Buttigliero C, Tucci M, Bertaglia V, et al. Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. Cancer Treat Rev. 2015 Dec;41(10):884–892. doi: 10.1016/j.ctrv.2015.08.002
   PubMed Web of Science ®Google Scholar
• Juvekar A, Burga LN, Hu H, et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov. 2012, Nov;2(11):1048–1063. doi: 10.1158/2159-8290.CD-11-0336
   PubMed Web of Science ®Google Scholar
• Carneiro BA, DeSouza A, Golijanin D, et al. BrUOG360: a phase Ib/II study of copanlisib combined with rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2022;40(6_suppl):128.
   Google Scholar
• Sweeney C, Bracarda S, Sternberg CN, et al. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2021 Jul 10;398(10295):131–142. doi: 10.1016/S0140-6736(21)00580-8
   PubMed Web of Science ®Google Scholar
• Fizazi K, George DJ, Santis MD, et al. A phase III trial of capivasertib and abiraterone versus placebo and abiraterone in patients with de novo metastatic hormone-sensitive prostate cancer characterized by PTEN deficiency (CAPItello-281). J Clin Oncol. 2021;39(6_suppl):TPS178.
   Web of Science ®Google Scholar
• Kase AM, Copland Iii JA, Tan W. Novel therapeutic strategies for CDK4/6 inhibitors in metastatic castrate-resistant prostate cancer Onco Targets Ther. 2020;13: 10499–10513.
   PubMed Web of Science ®Google Scholar
• Goel S, DeCristo MJ, McAllister SS, et al. CDK4/6 inhibition in cancer: beyond cell cycle arrest. Trends Cell Biol. 2018 Nov;28(11):911–925. doi: 10.1016/j.tcb.2018.07.002
   PubMed Web of Science ®Google Scholar
• Balk SP, Knudsen KE. AR, the cell cycle, and prostate cancer. Nucl Recept Signal. 2008 Feb 1;6(1):e001. doi: 10.1621/nrs.06001
   PubMedGoogle Scholar
• Agarwal N, Guana DC, Gordoa TA, et al. Abstract CT159: CYCLONE 1: abemaciclib in men with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC). Cancer Res. 2023;83(8_Supplement):CT159.
   Web of Science ®Google Scholar
• Smith MR, Agarwal N, Todenhöfer T, et al. CYCLONE 2: a phase 2/3, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2022;40(6_suppl):TPS198. doi: 10.1200/JCO.2022.40.6_suppl.TPS198
   Web of Science ®Google Scholar
• Smith MR, Matsubara N, McKay RR, et al. CYCLONE 3: a phase 3, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk, metastatic, hormone-sensitive prostate cancer (mHSPC). J Clin Oncol. 2023;41(6_suppl):TPS289.
   Google Scholar
• Rao A, Kwak L, Reimers MA, et al. A phase II trial of abemaciclib (abema) and atezolizumab (atezo) in unselected and CDK12-loss metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2022;40(6_suppl):TPS213.
   Web of Science ®Google Scholar
• Kelly WK, Godwin JL, Hoffman-Censits JH, et al. c15-153: randomized phase IB/II study of enzalutamide with and without ribociclib in patients with metastatic castrate resistant, chemotherapy naïve prostate cancer that retains RB expression. J Clin Oncol. 2018;36(6_suppl):TPS384.
   Web of Science ®Google Scholar
• Deeraksa A, Pan J, Sha Y, et al. Plk1 is upregulated in androgen-insensitive prostate cancer cells and its inhibition leads to necroptosis. Oncogene. 2013 Jun 13;32(24):2973–2983. doi: 10.1038/onc.2012.309
   PubMed Web of Science ®Google Scholar
• Zhang Z, Chen L, Wang H, et al. Inhibition of Plk1 represses androgen signaling pathway in castration-resistant prostate cancer. Cell Cycle. 2015;14(13):2142.
   PubMed Web of Science ®Google Scholar
• Patterson JC, Varkaris A, Croucher PJP, et al. Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling. Cancer Res. 2023 Jan 18;83(2):219–238. doi: 10.1158/0008-5472.CAN-22-1533
   PubMed Web of Science ®Google Scholar
• Einstein DJ, Choudhury AD, Saylor PJ, et al. A phase 2 study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2022;40(6_suppl):TPS219.
   Web of Science ®Google Scholar
• Wang P, Yuan Y, Lin W, et al. Roles of sphingosine-1-phosphate signaling in cancer. Cancer Cell Int. 2019;19(1):295.
   PubMed Web of Science ®Google Scholar
• Kucuk O, Smith C, Plasse T, et al. Phase II trial of opaganib in patients with metastatic castration-resistant prostate cancer progressing on abiraterone or enzalutamide (NCT04207255). J Clin Oncol. 2021;39(6_suppl):TPS191.
   Web of Science ®Google Scholar
• de Bono J, Mateo J, Fizazi K, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 May 28;382(22):2091–2102. doi: 10.1056/NEJMoa1911440
   PubMed Web of Science ®Google Scholar
• Abida W, Patnaik A, Campbell D, et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin Oncol. 2020 Nov 10;38(32):3763–3772. doi: 10.1200/JCO.20.01035
   PubMed Web of Science ®Google Scholar
• Clarke NW, Armstrong AJ, Thiery-Vuillemin A, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evi. 2022;1(9):EVIDoa2200043.
   Google Scholar
• Agarwal N, Azad AA, Carles J, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023 Jul 22;402(10398):291–303. doi: 10.1016/S0140-6736(23)01055-3
   PubMed Web of Science ®Google Scholar
• Chi KN, Rathkopf D, Smith MR, et al. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023 Jun 20;41(18):3339–3351. doi: 10.1200/JCO.22.01649
   PubMed Web of Science ®Google Scholar
• Agarwal N, Azad A, Fizazi K, et al. Talapro-3: a phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus enza in patients with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC). JCO. 2022/Feb/20;40(6_suppl):TPS221. doi: 10.1200/JCO.2022.40.6_suppl.TPS221
   Google Scholar
• Rathkopf DE, Chi KN, Olmos D, et al. AMPLITUDE: a study of niraparib in combination with abiraterone acetate plus prednisone (AAP) versus AAP for the treatment of patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC). Am Soc Clin Oncol. 2021;36(6_suppl). doi: 10.1200/JCO.2021.39.6_suppl.TPS176
   Google Scholar
• Karnitz LM, Zou L. Molecular pathways: targeting ATR in cancer therapy. Clin Cancer Res. 2015 Nov 1;21(21):4780–4785. doi: 10.1158/1078-0432.CCR-15-0479
   PubMed Web of Science ®Google Scholar
• Kim H, Xu H, George E, et al. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. Nat Commun. 2020 Jul 24;11(1):3726. doi: 10.1038/s41467-020-17127-2
   PubMed Web of Science ®Google Scholar
• Reichert ZR, Devitt ME, Alumkal JJ, et al. Targeting resistant prostate cancer, with or without DNA repair defects, using the combination of ceralasertib (ATR inhibitor) and olaparib (the TRAP trial). J Clin Oncol. 2022;40(6_suppl):88–88.
   Web of Science ®Google Scholar
• Choudhury AD, Xie W, Folefac E, et al. A phase 2 study of berzosertib (M6620) in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer. J Clin Oncol. 2021;39(15_suppl):5034–5034.
   Web of Science ®Google Scholar
• Illuzzi G, Staniszewska AD, Gill SJ, et al. Preclinical characterization of AZD5305, a next-generation, highly selective PARP1 inhibitor and trapper. Clin Cancer Res. 2022 Nov 1;28(21):4724–4736. doi: 10.1158/1078-0432.CCR-22-0301
   PubMed Web of Science ®Google Scholar
• Azad A, Voskoboynik M, Palma dos Reis AF, et al. Phase 1/2a study of AZD5305, a novel poly(adenosine diphosphate ribose) polymerase (PARP) 1-selective inhibitor in combination with new hormonal agents (NHAs) in patients (pts) with metastatic prostate cancer (mPC). J Clin Oncol. 2023;41(6_suppl):TPS296.
   Google Scholar
• Conteduca V, Hess J, Yamada Y, et al. Epigenetics in prostate cancer: clinical implications. Transl Androl Urol. 2021 Jul;10(7):3104–3116. doi: 10.21037/tau-20-1339
   PubMed Web of Science ®Google Scholar
• Park SH, Fong KW, Mong E, et al. Going beyond Polycomb: EZH2 functions in prostate cancer. Oncogene. 2021 Sep;40(39):5788–5798. doi: 10.1038/s41388-021-01982-4
   PubMed Web of Science ®Google Scholar
• Zhang X, Huo X, Guo H, et al. Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges. Front Pharmacol. 2022;13:965244. doi: 10.3389/fphar.2022.965244
   PubMed Web of Science ®Google Scholar
• Calvo M, Penkov K, Spira AI, et al. A multi-center, open-label, randomized dose expansion study of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2023;41(6_suppl):TPS282–TPS282.
   Google Scholar
• Choudhury AD, Xie W, Tewari A, et al. A phase Ia/Ib study of talazoparib in combination with tazemetostat in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2022;40(6_suppl):TPS195–TPS195.
   Web of Science ®Google Scholar
• Shi J, Vakoc CR. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Molecular Cell. 2014 Jun 5;54(5):728–736. doi: 10.1016/j.molcel.2014.05.016
   PubMed Web of Science ®Google Scholar
• Markowski MC, De Marzo AM, Antonarakis ES. BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations. Expert Opin Investig Drugs. 2017 Dec;26(12):1391–1397. doi: 10.1080/13543784.2017.1393518
   PubMed Web of Science ®Google Scholar
• Aggarwal RR, Schweizer MT, Nanus DM, et al. A randomized mCRPC phase 2b study of the BET bromodomain inhibitor (BETi) zen-3694 and enzalutamide vesus enzalutamide. J Clin Oncol. 2022;40(6_suppl):TPS201.
   Web of Science ®Google Scholar
• Hupe MC, Philippi C, Roth D, et al. Expression of prostate-specific membrane antigen (PSMA) on Biopsies is an Independent risk Stratifier of prostate cancer patients at time of Initial Diagnosis. Front Oncol. 2018;8:623. doi: 10.3389/fonc.2018.00623
   PubMed Web of Science ®Google Scholar
• Kratochwil C, Haberkorn U, Giesel FL. Radionuclide therapy of metastatic prostate cancer. Semin Nucl Med. 2019 Jul;49(4):313–325. doi: 10.1053/j.semnuclmed.2019.02.003
   PubMed Web of Science ®Google Scholar
• Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021 Sep 16;385(12):1091–1103. doi: 10.1056/NEJMoa2107322.
   PubMed Web of Science ®Google Scholar
• Sartor AO, Morris MJ, Chi KN, et al. Psmafore: a phase 3 study to compare 177Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2022;40(6_suppl):TPS211. doi: 10.1200/JCO.2022.40.6_suppl.TPS211.
   Google Scholar
• Sartor AO, Tagawa ST, Saad F, et al. Psmaddition: a phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2022;40(6_suppl):TPS210. doi: 10.1200/JCO.2022.40.6_suppl.TPS210
   Web of Science ®Google Scholar
• Dhiantravan N, Emmett L, Joshua AM, et al. UpFrontPSMA: a randomized phase 2 study of sequential (177) Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol). BJU Int. 2021 Sep;128(3):331–342. doi: 10.1111/bju.15384
   PubMed Web of Science ®Google Scholar
• Sandhu S, Joshua AM, Emmett L, et al. PRINCE: phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC). JCO. 2022 Jun 1;40(16_suppl):5017–5017. doi: 10.1200/JCO.2022.40.16_suppl.5017
   Google Scholar
• Sandhu S, Subramaniam S, Hofman MS, et al. Evolution: phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001). JCO. 2023/Feb/20;41(6_suppl):TPS271–TPS271. doi: 10.1200/JCO.2023.41.6_suppl.TPS271
   Google Scholar
• Sandhu S, Joshua AM, Emmett L, et al. LuPARP: phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC). JCO. 2023/Jun/1;41(16_suppl):5005–5005. doi: 10.1200/JCO.2023.41.16_suppl.5005
   Google Scholar
• Imber B, Bodei L, Humm J, et al. A Pilot study of stereotactic body radiotherapy and 177Lu-PSMA-617 for oligometastatic hormone sensitive prostate cancer. Int J Radiat Oncol Biol Phys. 2023;117(2):e112.
   Google Scholar
• Chi KN, Metser U, Czernin J, et al. Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using 177Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH). JCO. 2021/May/20;39(15_suppl):TPS5087. doi: 10.1200/JCO.2021.39.15_suppl.TPS5087
   Google Scholar
• Antonini P, Meyrick D, Hayward C. 177Lu-DOTA-TLX591 safety, biodistribution and dosimetry study (ProstACT-SELECT). JCO. 2022;40(16_suppl):TPS5109–TPS5109. doi: 10.1200/JCO.2022.40.16_suppl.TPS5109
   Web of Science ®Google Scholar
• Müller C, Umbricht CA, Gracheva N, et al. Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer. Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1919–1930. doi: 10.1007/s00259-019-04345-0
   PubMed Web of Science ®Google Scholar
• Buteau JP, Kostos LK, Alipour R, et al. VIOLET: a phase I/II trial evaluation of radioligand treatment in men with metastatic castration-resistant prostate cancer with [161Tb]Tb-PSMA-I&T. J Clin Oncol. 2023;41(6_suppl):TPS281.
   Google Scholar
• Yu EY, Laidley D, Pouliot F, et al. A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW). J Clin Oncol. 2020/May/20;38(15_suppl):TPS5596.
   Web of Science ®Google Scholar
• Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013 Jul 18;369(3):213–223. doi: 10.1056/NEJMoa1213755
   PubMed Web of Science ®Google Scholar
• Kostos L, Buteau JP, Yeung T, et al. AlphaBet: combination of radium-223 and [(17) (7)Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol). Front Med. 2022;9:1059122. doi: 10.3389/fmed.2022.1059122
   PubMed Web of Science ®Google Scholar
• Vis A, Ettema R, Hendrikse H, et al. A feasibility study of 177Lu-PSMA radioligand therapy alternated with radium-223 in patients with bone-metastatic, oligo-metastatic, hormone-sensitive prostate cancer after curative therapy: the DUET study. JCO. 2023/Jun/1;41(16_suppl):TPS5113–TPS5113. doi: 10.1200/JCO.2023.41.16_suppl.TPS5113
   Google Scholar
• Jang A, Kendi AT, Johnson GB, et al. Targeted alpha-particle therapy: a review of Current trials. Int J Mol Sci. 2023 Jul 19;24(14):11626. doi: 10.3390/ijms241411626
   PubMed Web of Science ®Google Scholar
• Tagawa ST, Sun M, Sartor AO, et al. Phase I study of 225Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2021;39(15_suppl):5015.
   Google Scholar
• Tagawa ST, Sun MP, Nauseef JT, et al. Phase I dose-escalation results of prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT) with alpha-radiolabeled antibody 225Ac-J591 and beta-radioligand 177Lu-PSMA I&T. J Clin Oncol. 2023;41(16_suppl):5018.
   Web of Science ®Google Scholar
• Sun MP, Nauseef JT, Palmer J, et al. Phase I results of a phase I/II study of pembrolizumab and AR signaling inhibitor (ARSI) with 225Ac-J591. J Clin Oncol. 2023;41(6_suppl):181.
   PubMedGoogle Scholar
• Morris MJ, Sartor AO, Wong JYC, et al. Phase 1 study of JNJ-69086420, an actinium-225-labeled antibody targeting human kallikrein-2, for advanced prostate cancer. J Clin Oncol. 2022;40(6_suppl):TPS206–TPS206.
   Web of Science ®Google Scholar
• Positive guidance from US FDA on Cu-64 SAR-bisPSMA phase III trial in prostate cancer: clarity pharmaceuticals; 2023 [cited 2023 Sep 1]. Available from: https://www.claritypharmaceuticals.com/news/clarify_fda/#:~:text=Clarity%20Pharmaceuticals%20%28ASX%3A%20CU6%29%20%28%E2%80%9CClarity%E2%80%9D%29%2C%20a%20clinical%20stage,with%20the%20US%20Food%20and%20Drug%20Administration%20%28FDA%29
   Google Scholar
• Lengyelova E, Wong V, Lenzo N, et al. 64Cu-SAR-bisPSMA (PROPELLER) positron emission tomography (PET) imaging in patients with confirmed prostate cancer. JCO. 2023;41(16_suppl):5039–5039. doi: 10.1200/JCO.2023.41.16_suppl.5039
   Web of Science ®Google Scholar
• Cella D, Peterman A, Hudgens S, et al. Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane). Cancer. 2003 Aug 15;98(4):822–831. doi: 10.1002/cncr.11578
   PubMed Web of Science ®Google Scholar
• Vaishampayan UN, Keessen M, Shore ND, et al. Phase IIb trial of oral ModraDoc006/r as a tolerable and effective option in comparison with intravenous docetaxel in metastatic castration-resistant prostate cancer (mCRPC). JCO. 2021/2/Aug;39(6_suppl):132–132. doi: 10.1200/JCO.2021.39.6_suppl.132
   Google Scholar
• Markowski MC, Eisenberger MA, Pieczonka CM, et al. The role of sabizabulin in phase 1b/2 clinical trials of men with metastatic castration-resistant prostate cancer who progressed on androgen receptor-targeting agents. JCO. 2022 Feb 20;40(6_suppl):110–110. doi: 10.1200/JCO.2022.40.6_suppl.110
   Google Scholar
• Dreicer R, Chu F, Cahn DJ, et al. Phase 3 VERACITY clinical study of sabizabulin in men with metastatic castrate resistant prostate cancer who have progressed on an androgen receptor targeting agent. JCO. 2022/Feb/20;40(6_suppl):TPS217. doi: 10.1200/JCO.2022.40.6_suppl.TPS217
   Google Scholar
• Della Salda L, Massimini M, Romanucci M, et al. Nectin-4 and p63 immunohistochemical expression in canine prostate tumourigenesis. Vet Comparative Oncology. 2019 Sep;17(3):298–307. doi: 10.1111/vco.12469
   PubMed Web of Science ®Google Scholar
• Shen M, Liu S, Stoyanova T. The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target. Am J Clin Exp Urol. 2021;9(1):73–87.
   PubMed Web of Science ®Google Scholar
• Lang JM, Kyriakopoulos C, Slovin SF, et al. Single-arm, phase II study to evaluate the safety and efficacy of sacituzumab govitecan in patients with metastatic castration-resistant prostate cancer who have progressed on second generation AR-directed therapy. JCO. 2020 Feb 20;38(6_suppl):TPS251. doi: 10.1200/JCO.2020.38.6_suppl.TPS251
   Google Scholar
• Guo C, Figueiredo I, Gurel B, et al. B7-H3 as a therapeutic target in advanced prostate cancer. Eur Urol. 2023 Mar;83(3):224–238. doi: 10.1016/j.eururo.2022.09.004
   PubMedGoogle Scholar
• Shi X, Day A, Bergom HE, et al. Integrative molecular analyses define correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancer. Npj Precis Onc. 2022 Nov 2;6(1):80. doi: 10.1038/s41698-022-00323-2
   PubMed Web of Science ®Google Scholar
• Patel MR, Johnson ML, Falchook GS, et al. DS-7300 (B7-H3 DXd-ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): a subgroup analysis of a phase 1/2 multicenter study. JCO. 2022 Feb 20;40(6_suppl):87–87. doi: 10.1200/JCO.2022.40.6_suppl.087
   Google Scholar
• Su Y, Liu Y, Behrens CR, et al. Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. JCI Insight. 2018 Sep 6;3(17). doi: 10.1172/jci.insight.121497
   Web of Science ®Google Scholar
• Lue HW, Yang X, Wang R, et al. LIV-1 promotes prostate cancer epithelial-to-mesenchymal transition and metastasis through HB-EGF shedding and EGFR-mediated ERK signaling. PLoS One. 2011;6(11):e27720.
   PubMed Web of Science ®Google Scholar
• Sher AF, Bruce JY, Gabrail NY, et al. Open-label, phase II study of ladiratuzumab vedotin (LV) for castration-resistant prostate cancer (SGNLVA-005, trial-in-progress). JCO. 2021/Feb/20;39(6_suppl):TPS185–TPS185. doi: 10.1200/JCO.2021.39.6_suppl.TPS185
   Google Scholar
• Sfanos KS, Bruno TC, Maris CH, et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res. 2008 Jun 1;14(11):3254–3261. doi: 10.1158/1078-0432.CCR-07-5164
   PubMed Web of Science ®Google Scholar
• Lanka SM, Zorko NA, Antonarakis ES, et al. Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond. Curr Oncol. 2023 Apr 19;30(4):4246–4256. doi: 10.3390/curroncol30040323
   PubMed Web of Science ®Google Scholar
• Goebeler ME, Bargou RC. T cell-engaging therapies - BiTEs and beyond. Nat Rev Clin Oncol. 2020 Jul;17(7):418–434. doi: 10.1038/s41571-020-0347-5
   PubMed Web of Science ®Google Scholar
• Kelly WK, Thanigaimani P, Sun F, et al. A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer. JCO. 2022/Jun/1;40(16_suppl):TPS5105. doi: 10.1200/JCO.2022.40.16_suppl.TPS5105
   Google Scholar
• Buelow B, Dalvi P, Dang K, et al. TNB585.001: a multicenter, phase 1, open-label, dose-escalation and expansion study of tnb-585, a bispecific T-cell engager targeting PSMA in subjects with metastatic castrate resistant prostate cancer. JCO. 2021/May/20;39(15_suppl):TPS5092. doi: 10.1200/JCO.2021.39.15_suppl.TPS5092
   Google Scholar
• Hackenbruch C, Heitmann JS, Walz JS, et al. ProSperA: phase I study to evaluate safety, tolerability and preliminary efficacy of a bispecific PSMAxCD3 antibody in men with biochemical recurrence of prostate cancer. JCO. 2023;41(16_suppl):TPS5114. doi: 10.1200/JCO.2023.41.16_suppl.TPS5114
   Web of Science ®Google Scholar
• Lim EA, Schweizer MT, Chi KN, et al. Phase 1 study of safety and preliminary Clinical activity of JNJ-63898081, a PSMA and CD3 bispecific antibody, for metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2023 Jun;21(3):366–375. doi: 10.1016/j.clgc.2023.02.010
   PubMed Web of Science ®Google Scholar
• Stein MN, Zhang J, Kelly WK, et al. Preliminary results from a phase 1/2 study of co-stimulatory bispecific PSMAxCD28 antibody REGN5678 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). JCO. 2023/Feb/20;41(6_suppl):154–154. doi: 10.1200/JCO.2023.41.6_suppl.154
   Google Scholar
• Mehra N, Robbrecht D, Voortman J, et al. Early dose escalation of LAVA-1207, a novel bispecific gamma-delta T-cell engager (Gammabody), in patients with metastatic castration-resistant prostate cancer (mCRPC). JCO. 2023/Feb/20;41(6_suppl):153–153. doi: 10.1200/JCO.2023.41.6_suppl.153
   Google Scholar
• Park JH, Lee HK. Function of γδ T cells in tumor immunology and their application to cancer therapy. Exp Mol Med. 2021 Mar;53(3):318–327. doi: 10.1038/s12276-021-00576-0
   PubMed Web of Science ®Google Scholar
• Hubert RS, Vivanco I, Chen E, et al. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14523–14528. doi: 10.1073/pnas.96.25.14523
   PubMed Web of Science ®Google Scholar
• Puca L, Gavyert K, Sailer V, et al. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Sci, trans med. 2019 Mar 20;11(484). doi: 10.1126/scitranslmed.aav0891
   PubMed Web of Science ®Google Scholar
• Aggarwal RR, Aparicio A, Heidenreich A, et al. Phase 1b study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTEimmune-oncology therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC). JCO. 2021/May/20;39(15_suppl):TPS5100–TPS5100. doi: 10.1200/JCO.2021.39.15_suppl.TPS5100
   Google Scholar
• Allen C, Zeidan AM, Bewersdorf JP. BiTEs, DARTS, BiKEs and TriKEs—are antibody based therapies changing the future treatment of AML? Life (Basel). 2021 May 23;11(6):465. doi: 10.3390/life11060465
   PubMed Web of Science ®Google Scholar
• Luke JJ, Sharma M, Chandana SR, et al. Lorigerlimab, a bispecific PD-1×CTLA-4 DART molecule in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): a phase 1 expansion (exp) cohort. JCO. 2023/Feb/20;41(6_suppl):155–155. doi: 10.1200/JCO.2023.41.6_suppl.155
   Google Scholar
• Patel U, Abernathy J, Savani BN, et al. CAR T cell therapy in solid tumors: a review of current clinical trials. EJHaem. 2022, Jan;3(Suppl S1):24–31. doi: 10.1002/jha2.356
   PubMedGoogle Scholar
• Dorff TB, Blanchard S, Martirosyan H, et al. Phase 1 study of PSCA-targeted chimeric antigen receptor (CAR) T cell therapy for metastatic castration-resistant prostate cancer (mCRPC). JCO. 2022/Feb/20;40(6_suppl):91–91. doi: 10.1200/JCO.2022.40.6_suppl.091
   Google Scholar
• Dorff TB, Blanchard S, Martirosyan H, et al. Final results from phase I study of PSCA-targeted chimeric antigen receptor (CAR) T cells in patients with metastatic castration resistant prostate cancer (mCRPC). JCO. 2023/Jun/01;41(16_suppl):5019–5019. doi: 10.1200/JCO.2023.41.16_suppl.5019
   Google Scholar
• Slovin SF, Dorff TB, Falchook GS, et al. Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC). JCO. 2022/Feb/20;40(6_suppl):98–98. doi: 10.1200/JCO.2022.40.6_suppl.098
   Google Scholar
• Bellicum discontinues phase 1/2 trials and initiates evaluation of strategic alternatives: bellicum; 2023 [cited 2023 Sep 12]. Available from: https://ir.bellicum.com/news-releases/news-release-details/bellicum-discontinues-phase-12-trials-and-initiates-evaluation
   Google Scholar
• McKean M, Carabasi MH, Stein MN, et al. Safety and early efficacy results from a phase 1, multicenter trial of PSMA-targeted armored CAR T cells in patients with advanced mCRPC. JCO. 2022;40(6_suppl):94.
   Web of Science ®Google Scholar
• Araki S, Omori Y, Lyn D, et al. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res. 2007 Jul 15;67(14):6854–6862. doi: 10.1158/0008-5472.CAN-07-1162
   PubMed Web of Science ®Google Scholar
• Maynard JP, Ertunc O, Kulac I, et al. IL8 expression is associated with prostate cancer aggressiveness and androgen receptor loss in primary and metastatic prostate cancer. Mol Cancer Res. 2020 Jan;18(1):153–165. doi: 10.1158/1541-7786.MCR-19-0595
   PubMed Web of Science ®Google Scholar
• Dallos M, Pan SM, Chaimowitz M, et al. A randomized phase Ib/II study of intermittent androgen deprivation therapy plus nivolumab with or without interleukin-8 blockade in men with hormone-sensitive prostate cancer (MAGIC-8). JCO. 2022/Jun/1;40(16_suppl):5082–5082. doi: 10.1200/JCO.2022.40.16_suppl.5082
   Google Scholar
• Calcinotto A, Spataro C, Zagato E, et al. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature. 2018 Jul;559(7714):363–369. doi: 10.1038/s41586-018-0266-0
   PubMed Web of Science ®Google Scholar
• Näslund-Koch C, Zachariae C, Skov L. tildrakizumab: an Evidence-based Review of its use in the treatment of moderate-to-severe chronic plaque psoriasis. TCRM. 2020;16:903–916. doi: 10.2147/TCRM.S227880
   Google Scholar
• Guo C, Crabb SJ, Pacey S, et al. A phase (Ph) I/II trial of abiraterone acetate in combination with tildrakizumab (anti-IL23 monoclonal antibody) in patients with metastatic castration-resistant prostate cancer (mCRPC). JCO. 2023/Jun/1;41(16_suppl):TPS5105–TPS5105. doi: 10.1200/JCO.2023.41.16_suppl.TPS5105
   Google Scholar
• Nguyen KG, Vrabel MR, Mantooth SM, et al. Localized interleukin-12 for cancer immunotherapy. Front Immunol. 2020;11:575597. doi: 10.3389/fimmu.2020.575597
   PubMed Web of Science ®Google Scholar
• Atiq MO, Chandran EBA, Meininger L, et al. Safety evaluation of M9241 in combination with docetaxel in metastatic prostate cancer. JCO. 2022/Feb/20;40(6_suppl):93–93. doi: 10.1200/JCO.2022.40.6_suppl.093
   Google Scholar
• Harjunpää H, Guillerey C. TIGIT as an emerging immune checkpoint. Clin Exp Immunol. 2020 May;200(2):108–119. doi: 10.1111/cei.13407
   PubMed Web of Science ®Google Scholar
• Shore ND, De Bono JS, Kramer G, et al. KEYNOTE-365 cohorts G and H: phase 1b/2 study of pembrolizumab + vibostolimab combination therapy in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE). JCO. 2022/Feb/20;40(6_suppl):TPS204–TPS204. doi: 10.1200/JCO.2022.40.6_suppl.TPS204
   Google Scholar
• Sun C, Wang B, Hao S. Adenosine-A2A receptor pathway in cancer immunotherapy. Front Immunol. 2022;13:837230. doi: 10.3389/fimmu.2022.837230
   PubMed Web of Science ®Google Scholar
• Zhang J, Aggarwal RR, Tagawa ST, et al. BXCL701: first-in-class oral activator of systemic innate immunity combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of adenocarcinoma phenotype—phase 2a results. JCO. 2022/Feb/20;40(6_suppl):125–125. doi: 10.1200/JCO.2022.40.6_suppl.125
   Google Scholar
• Aggarwal RR, Zhang J, Monk P, et al. First-in-class oral innate immune activator BXCL701 combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) variant: randomized phase 2b trial. JCO. 2023/Jun/1;41(16_suppl):TPS5109. doi: 10.1200/JCO.2023.41.16_suppl.TPS5109
   Google Scholar
• Yamazaki T, Buqué A, Ames TD, et al. PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models. Oncoimmunology. 2020;9(1):1721810.
   PubMed Web of Science ®Google Scholar
• Bryce AH, Karp DD, Tagawa ST, et al. A phase 2 study of immunogenic cell death inducer PT-112 in patients with metastatic castration-resistant prostate cancer. JCO. 2023/Feb/20;41(6_suppl):TPS292. doi: 10.1200/JCO.2023.41.6_suppl.TPS292
   Google Scholar
• Stein MN, Dorff TB, Goodman OB, et al. A phase 2, multicenter, parallel-group, open-label study of vudalimab (XmAb20717), a PD-1 x CTLA-4 bispecific antibody, alone or in combination with chemotherapy or targeted therapy in patients with molecularly defined subtypes of metastatic castration-resistant prostate cancer. J Clin Oncol. 2022/Jun/1;40(16_suppl):TPS5097–TPS5097.
   Google Scholar
• Murphy CG. The role of CDK4/6 inhibitors in breast cancer. Current treatment options in oncology. Curr Treat Options Oncol. 2019 May 18;20(6):52. doi: 10.1007/s11864-019-0651-4
   PubMedGoogle Scholar